Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 14, 2026 14:20 ET | Source: Hagens Berman Sobol Shapiro LLP

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate– Hagens Berman

Investors who lost money in AARD after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman.
April 28, 2026 11:51 ET | Source: Hagens Berman Sobol Shapiro LLP

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate– Hagens Berman

Investors who lost money in AARD after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman.
April 14, 2026 12:52 ET | Source: Hagens Berman Sobol Shapiro LLP

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate– Hagens Berman

Investors who lost money in AARD after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman.
April 09, 2026 19:26 ET | Source: Hagens Berman Sobol Shapiro LLP

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate– Hagens Berman

Investors who lost money in AARD after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman.
February 12, 2026 08:00 ET | Source: Aardvark Therapeutics, Inc.

Aardvark Therapeutics Announces Leadership Appointments

Aardvark Therapeutics Announces Leadership Appointments
February 12, 2026 08:00 ET | Source: Aardvark Therapeutics, Inc.

Aardvark Therapeutics Announces Establishment of New U.S. Subsidiary to Support Development of Its Dermatology Pipeline; Bryan Jones Named Chief Executive Officer

Aardvark Therapeutics Announces Establishment of New U.S. Subsidiary; Bryan Jones Named Chief Executive Officer
February 10, 2026 08:00 ET | Source: Aardvark Therapeutics, Inc.

Aardvark Therapeutics Announces FDA Submission and IRB Approval of Amended Trial Protocol for Lead Candidate ARD-101, Expanding Eligibility in Phase 3 Study of Prader-Willi Syndrome

Aardvark Therapeutics announced a Phase 3 HERO trial protocol amendment expanding eligibility for patients with Prader-Willi Syndrome.